A Study of RX108 in Patients With Locally Advanced or Metastatic Solid Tumors
Status:
Recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
RX108 is a novel, potent, small-molecule inhibitor of Na+/K+-ATPase. The purpose of this
study is to evaluate the safety, tolerability, pharmacokinetics (PK) and efficacy of RX108 in
patients with locally advanced or metastatic solid tumors.